IN8bio
INAB
32 hedge funds and large institutions have $10.2M invested in IN8bio in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
10% more funds holding
Funds holding: 29 → 32 (+3)
0.23% less ownership
Funds ownership: 0.89% → 0.67% (-0.23%)
10% less capital invested
Capital invested by funds: $11.4M → $10.2M (-$1.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$481K |
| 3 |
Renaissance Technologies
New York
|
+$125K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$102K |
| 5 |
Millennium Management
New York
|
+$40.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.54M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$470K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$27.3K |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$22.3K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$14K |
INAB Hedge Fund Activity: Q1 2024 in Review
32 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q1 2024, worth a combined $10.2M — down 10% from $11.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INAB positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.27M. The largest seller was AIGH Capital Management, cutting an estimated $1.54M.
- 32 institutional investors held IN8bio (INAB) as of Q1 2024, up from 29 in Q4 2023.
- Funds reported $10.2M of IN8bio stock for Q1 2024, down 10% quarter-over-quarter.
- 6 funds opened new IN8bio positions in Q1 2024 and 3 closed out, a net change of +3 holders.
- The largest IN8bio buyer in Q1 2024 was Vanguard Group, an estimated $1.27M added.
- The largest IN8bio seller in Q1 2024 was AIGH Capital Management, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2024.